Vaxart, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
Vaxart, Inc. (VXRT) reported Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized of 3.00 million shares for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized · last filed 2024-05-13
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2024-03-31 was 3.00M shares.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2021-12-31 was 0.00 shares.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2021-09-30 was 0.00 shares.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2020-12-31 was 0.00 shares.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for fiscal 2022 was 12.00M shares, a 34.83% increase from fiscal 2021.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for fiscal 2021 was 8.90M shares, a 39.06% increase from fiscal 2020.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for fiscal 2020 was 6.40M shares, a 300.00% increase from fiscal 2019.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, number of additional shares authorized for fiscal 2019 was 1.60M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 12 month |
|---|---|---|---|---|
| 2024-03-31 | 3.00M shares 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | 12.00M shares 10-K · filed 2024-03-14 | |||
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 0.00 shares derived: sum of 2 quarters · filed 2023-03-15 | 8.90M shares 10-K · filed 2023-03-15 | |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 8.90M shares 10-Q · filed 2021-11-04 | ||
| 2021-06-30 | 8.90M shares 10-Q · filed 2021-08-05 | |||
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 0.00 shares derived: sum of 2 quarters · filed 2022-02-24 | 6.40M shares 10-K · filed 2022-02-24 | |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | 6.40M shares 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | 6.40M shares 10-Q · filed 2020-08-06 | |||
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 0.00 shares derived: sum of 2 quarters · filed 2022-02-24 | 1.60M shares 10-K · filed 2022-02-24 | |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | 1.60M shares 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | 1.60M shares 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |